IM Therapeutics is a company that develops personalized immuno-therapeutic drugs. It offers an oral drug that starves the autoimmune process in type 1 diabetes (T1D) by blocking DQ8 on specific immune cells. The company aims to preserve pancreatic beta-cell function and maintain normal insulin production in at-risk and early-stage patients with type 1 diabetes.